James Heslop to Humans
This is a "connection" page, showing publications James Heslop has written about Humans.
Connection Strength
0.142
-
GATA6 defines endoderm fate by controlling chromatin accessibility during differentiation of human-induced pluripotent stem cells. Cell Rep. 2021 05 18; 35(7):109145.
Score: 0.029
-
The Use of Human Pluripotent Stem Cells for Modeling Liver Development and Disease. Hepatology. 2019 03; 69(3):1306-1316.
Score: 0.025
-
Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. Stem Cells Transl Med. 2017 05; 6(5):1321-1331.
Score: 0.022
-
Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. Arch Toxicol. 2017 Jan; 91(1):439-452.
Score: 0.020
-
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med. 2015 Apr; 4(4):389-400.
Score: 0.019
-
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023 Mar; 615(7950):134-142.
Score: 0.008
-
PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression. J Biol Chem. 2020 12 25; 295(52):18091-18104.
Score: 0.007
-
MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. Toxicol Sci. 2015 Mar; 144(1):173-85.
Score: 0.005
-
Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol. 2013 Apr; 75(4):885-96.
Score: 0.004
-
Human pluripotent stem cells for modeling toxicity. Adv Pharmacol. 2012; 63:207-56.
Score: 0.004